Long-acting injectable antipsychotics in early psychosis: a literature review

Robin Emsley*, Bonginkosi Chiliza, Laila Asmal, Mpogisheng Mashile, Paolo Fusar-Poli

*Corresponding author for this work

Research output: Contribution to journalLiterature reviewpeer-review

50 Citations (Scopus)

Abstract

Aim: There are sound reasons for considering the use of long-acting injectable antipsychotics early in the course of schizophrenia. We reviewed available literature on the subject.

Method: We conducted an electronic database search and critically reviewed all studies in which a long-acting injectable antipsychotic was evaluated in early psychosis patients.

Results: There is a need for well-designed studies as most of those reported were open-label and non-comparative, and samples were frequently small.

Conclusions: The available evidence does suggest that long-acting injectable antipsychotics can be used safely and effectively in early stages of the illness, and that they may be associated with better outcomes than with oral medications. However, this is largely supported by evidence from naturalistic cohort studies and a small number of controlled trials of risperidone long-acting injection. Evidence for olanzapine and paliperidone longacting injectables in particular is limited.

Original languageEnglish
Pages (from-to)247-254
Number of pages8
JournalEarly Intervention in Psychiatry
Volume7
Issue number3
DOIs
Publication statusPublished - Aug 2013

Keywords

  • depot
  • early psychosis
  • long-acting antipsychotic
  • schizophrenia
  • OPEN-LABEL TRIAL
  • 1ST-EPISODE SCHIZOPHRENIA
  • PRODROMAL SIGNS
  • 1ST EPISODE
  • RISPERIDONE
  • DISORDERS
  • REMISSION
  • INJECTION
  • VULNERABILITY
  • MEDICATION

Fingerprint

Dive into the research topics of 'Long-acting injectable antipsychotics in early psychosis: a literature review'. Together they form a unique fingerprint.

Cite this